AVEO Oncology Reports Third Quarter 2020 Financial Results and Provides Business Update
AVEO Oncology (Nasdaq: AVEO) today reported financial results for the third quarter ended September 30, 2020 and provided a business update.
- AVEO Oncology (Nasdaq: AVEO) today reported financial results for the third quarter ended September 30, 2020 and provided a business update.
- Announced Publication of Results from Phase 1b/2 TiNivo Study of Tivozanib in Combination with OPDIVO (nivolumab) in RCC in Annals of Oncology.
- In connection with these preparations, in October 2020, AVEO announced the appointment of David W. Crist as vice president of sales.
- While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.